Robert Bhatt

Robert Bhatt has been instrumental in defining and treating HER2-low breast cancer, a newly recognized therapeutic subtype constituting over 50% of metastatic breast cancers. His translational research contributed to the DESTINY-Breast04 trial showing dramatic benefit of trastuzumab deruxtecan in HER2-low disease. He has studied the clinical and molecular heterogeneity of HER2-low expression and its interaction with hormone receptor status. His work has fundamentally expanded the population of breast cancer patients who can benefit from HER2-directed ADC therapy.